265 related articles for article (PubMed ID: 17785116)
21. Introduction of OX40 ligand into lymphoma cells elicits anti-lymphoma immunity in vivo.
Kaneko H; Hori T; Yanagita S; Kadowaki N; Uchiyama T
Exp Hematol; 2005 Mar; 33(3):336-43. PubMed ID: 15730857
[TBL] [Abstract][Full Text] [Related]
22. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapeutic potential of two gallic acid derivative compounds from leaves of Casearia sylvestris Sw (Flacourtiaceae).
Da Silva SL; Chaar Jda S; Yano T
Eur J Pharmacol; 2009 Apr; 608(1-3):76-83. PubMed ID: 19222998
[TBL] [Abstract][Full Text] [Related]
24. [Influences of FVP1 on the curative and negative effects of CTX].
Yuan Q; Chen ZY; Yan MX
Zhongguo Zhong Yao Za Zhi; 2005 Jun; 30(12):933-5. PubMed ID: 16124615
[TBL] [Abstract][Full Text] [Related]
25. Prediction of in vivo tumor response to chemotherapeutic agents by the in vitro sister chromatid exchange assay.
Tofilon PJ; Basic I; Milas L
Cancer Res; 1985 May; 45(5):2025-30. PubMed ID: 4039220
[TBL] [Abstract][Full Text] [Related]
26. Melphalan-induced DNA damage in p53(+/-) and wild type mice analysed by the comet assay.
Cordelli E; Cinelli S; Lascialfari A; Ranaldi R; Pacchierotti F
Mutat Res; 2004 Jun; 550(1-2):133-43. PubMed ID: 15135647
[TBL] [Abstract][Full Text] [Related]
27. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.
Teicher BA; Ikebe M; Ara G; Keyes SR; Herbst RS
In Vivo; 1997; 11(6):463-72. PubMed ID: 9509296
[TBL] [Abstract][Full Text] [Related]
28. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
Pogrebniak A; Schemainda I; Azzam K; Pelka-Fleischer R; Nüssler V; Hasmann M
Eur J Med Res; 2006 Aug; 11(8):313-21. PubMed ID: 17052966
[TBL] [Abstract][Full Text] [Related]
29. Optimizing the factors which modify thermal enhancement of melphalan in a spontaneous murine tumor.
Mohamed F; Stuart OA; Glehen O; Urano M; Sugarbaker PH
Cancer Chemother Pharmacol; 2006 Dec; 58(6):719-24. PubMed ID: 16614851
[TBL] [Abstract][Full Text] [Related]
30. Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models.
Zheng LM; Li Z; Liu L; Song BL; King I
Cancer Chemother Pharmacol; 2007 Jun; 60(1):45-51. PubMed ID: 17256135
[TBL] [Abstract][Full Text] [Related]
31. [Antitumor effect of recombinant Xenopus laevis vascular endothelial growth factor (VEGF) as a vaccine combined with adriamycin on EL4 lymphoma in mice].
Niu T; Liu T; Jia YQ; Liu JY; Wu Y; Hu B; Tian L; Yang L; Kan B; Wei YQ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Sep; 36(5):661-4, 675. PubMed ID: 16235531
[TBL] [Abstract][Full Text] [Related]
32. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
Song Y; Shen K; Yu JR
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
[TBL] [Abstract][Full Text] [Related]
33. Prevention of the development of melphalan resistance in vitro by selenite.
Caffrey PB; Zhu M; Frenkel GD
Biol Trace Elem Res; 1998 Dec; 65(3):187-95. PubMed ID: 9892492
[TBL] [Abstract][Full Text] [Related]
34. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms.
Marchini S; Damia G; Broggini M; Pennella G; Ripamonti M; Marsiglio A; Geroni C
Cancer Res; 2001 Mar; 61(5):1991-5. PubMed ID: 11280757
[TBL] [Abstract][Full Text] [Related]
35. Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan.
Mortara L; Balza E; Sassi F; Castellani P; Carnemolla B; De Lerma Barbaro A; Fossati S; Tosi G; Accolla RS; Borsi L
Eur J Immunol; 2007 Dec; 37(12):3381-92. PubMed ID: 18022863
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of fluorenhymustine as a rationally designed novel anticancer agent.
Samanta S; Pain A; Ghosh M; Dutta S; Sanyal U
Exp Oncol; 2005 Dec; 27(4):279-85. PubMed ID: 16404347
[TBL] [Abstract][Full Text] [Related]
37. [Antitumour effect of total saponins of Rubus parvifolius on malignant melanoma].
Zheng ZX; Zhang LJ; Huang CX; Huang QL; Wei XD; Wu XY; Zhou WM
Zhongguo Zhong Yao Za Zhi; 2007 Oct; 32(19):2055-8. PubMed ID: 18161304
[TBL] [Abstract][Full Text] [Related]
38. Treatment of human ovarian tumor xenografts with selenite prevents the melphalan-induced development of drug resistance.
Caffrey PB; Frenkel GD
Anticancer Res; 1998; 18(4C):3017-20. PubMed ID: 9713502
[TBL] [Abstract][Full Text] [Related]
39. [Rhodiola sachalinensis suppresses T241 fibrosarcoma tumor cells proliferation in vitro and growth in vivo].
Zhao X; Zuo L; Zhong ZQ
Zhong Yao Cai; 2008 Sep; 31(9):1377-80. PubMed ID: 19180963
[TBL] [Abstract][Full Text] [Related]
40. Systemic treatment with n-6 polyunsaturated fatty acids attenuates EL4 thymoma growth and metastasis through enhancing specific and non-specific anti-tumor cytolytic activities and production of TH1 cytokines.
Salem ML
Int Immunopharmacol; 2005 Jun; 5(6):947-60. PubMed ID: 15829411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
